Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $8 | $7 | $14 |
| - Cash | $2 | $2 | $2 | $3 |
| + Debt | $3 | $4 | $6 | $6 |
| Enterprise Value | $6 | $9 | $12 | $17 |
| Revenue | $5 | $5 | $7 | $6 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Gross Profit | $2 | $1 | $2 | $2 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| EBITDA | $1 | -$0 | $1 | $1 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |
| Net Income | $1 | -$1 | $1 | $0 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| Operating Cash Flow | $2 | $0 | -$1 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $2 | -$0 | -$1 | -$0 |